Potentially Inappropriate Prescribing Among Older Persons: A Meta-Analysis of Observational Studies

Potentially inappropriate prescribing (PIP) in older adults was significantly negatively associated with emergency room visits, adverse drug events, functional decline, health-related quality of life, and hospitalizations. This meta-analysis highlights the need to identify PIP in primary care and calls for further research on PIP interventions in primary care. Read More →

Read More
Brea Neri
Biochemical Urine Testing of Adherence to Cardiovascular Medications Reveals High Rates of Nonadherence in People Attending Their Annual Review for Type 2 Diabetes

Routine urine samples, received at the time of the annual diabetes review from people with type 2 diabetes in primary care, were assessed for adherence by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and found 28.1% of patients to be nonadherent to antidiabetic, antihypertensive, and/or lipid-lowering medications. This unique study shows that routine urine samples can be used for adherence testing screening by LC-MS/MS. Read More →

Read More
Brea Neri
Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study

The LDL threshold of < 100mg/dl was not achieved in 33.7% of patients initiated on a statin in the general cohort while the LDL threshold of < 70mg/dl was not achieved in 58.1% of patient initiated on a statin in the secondary prevention cohort. This study has shown a large and potentially important gap between reasonable LDL-C thresholds and actual LDL-C levels achieved by contemporary statin regimens. Read More →

Read More
Brea Neri
Exeltis USA, Inc. Announces the Approval of Slynd (drospirenone), the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24/4 Dosing Regimen and 24-hour Missed Pill Window

FDA approved the new drug application (NDA) for Slynd (pronounced "slind") containing drospirenone 4 mg, an oral contraceptive tablet for pregnancy prevention. Slynd is the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24/4 Dosing Regimen and 24-hour Missed Pill Window. This not only can mean favorable safety and efficacy but an improved bleeding profile and contraceptive efficacy for up to 24 hours in the event of a delayed or missed dose. Read More →

Read More
Brea Neri
FDA Approves Nayzilam

FDA approved the anti-epileptic drug (AED) Nayzilam (midazolam) nasal spray CIV, a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older. Nayzilam now provides patients and caregivers with the first and only FDA-approved nasal option for treating seizure clusters. Read More →

Read More
Brea Neri
Drug Overdose Deaths Involving Cocaine and Psychostimulants with Abuse Potential — United States, 2003–2017

During 2015–2016, age-adjusted cocaine-involved and psychostimulant-involved death rates increased by 52.4% and 33.3%, respectively. From 2016 to 2017, death rates involving cocaine and psychostimulants, with and without opioids, have continued to increase. These increases in stimulant-involved deaths require expanded surveillance and comprehensive, evidence-based public health and public safety interventions. Read More →

Read More
Brea Neri
Association of High Intakes of Vitamins B6 and B12 From Food and Supplements With Risk of Hip Fracture Among Postmenopausal Women in the Nurses’ Health Study

In this cohort study, a combined high intake of vitamins B6 and B12 was associated with an increased risk of hip fracture. The intakes were far higher than the recommended dietary allowances. These findings add to previous studies suggesting that vitamin supplements should be used cautiously because adverse effects can occur. Read More →

Read More
Brea Neri
Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline

BMJ - guideline panel issues a strong recommendation against thyroid hormones in adults with subclinical hypothyroidism (elevated TSH levels and normal free T4 (thyroxine) levels). It does not apply to women who are trying to become pregnant or patients with TSH >20 mIU/L. It may not apply to patients with severe symptoms or young adults (such as those ≤30 years old). Read More →

Read More
Brea Neri
Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose

States adopting naloxone access laws granting direct authority to pharmacists experienced statistically significant declines in fatal opioid-related overdoses. Other types of naloxone access laws appear not to be associated with decreases or increases in mortality. Communities in which access to naloxone is improved should prepare for increases in nonfatal overdoses and link these individuals to effective treatment. Read More →

Read More
Brea Neri
FDA Approves Eticovo (etanercept-ykro), a Biosimilar to Enbrel

FDA - approved Eticovo (etanercept-ykro), a biosimilar referencing Enbrel (etanercept), across all eligible indications for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis and polyarticular juvenile idiopathic arthritis. Eticovo has demonstrated comparable safety and efficacy to the etanercept reference product (Enbrel®). Read More →

Read More
Brea Neri